IMTXImmatics N.V.

IMTX Stock Price, Valuation & Chart | Immatics N.V.

Compare

$9.500+0.07 (+0.74%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology IMTX intrinsic value IMTX calculated fair value vs price

Overview Financials Dividends Ratios

IMTX Historical price chart

IMTX Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization1.27B

PE Ratio-5.11

EPS-1.86

Trading Volume736.11K

Today's High/Low9.72/9.29

Dividend Yield0.00

52 Week High/Low12.41/5.29

Shares Outstanding134.10M

IMTX Financial Statement

IMTX Analyst ratings

IMTX Analysis & performance metrics

IMTX Company profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer…

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR…

IMTX Management team

Name

Position

Carsten Reinhardt M.D., Ph.D.

Chief Development Officer

Edward A. Sturchio

General Counsel & Secretary

Toni Weinschenk Ph.D.

Co-Founder & Chief Innovation Officer

Cedrik M. Britten M.D.

Chief Medical Officer

Jordan Silverstein

Head of Strategy

Hans-Georg Rammensee Ph.D.

Co-Founder & Member of the Scientific Advisory Board

Harpreet Singh Ph.D.CEO

Chief Executive Officer, MD, Member of Management Board & Executive Director

Arnd Christ MBACFO

Chief Financial Officer

Name

Position

Carsten Reinhardt M.D., Ph.D.

Chief Development Officer

Edward A. Sturchio

General Counsel & Secretary

Toni Weinschenk Ph.D.

Co-Founder & Chief Innovation Officer

Cedrik M. Britten M.D.

Chief Medical Officer

Jordan Silverstein

Head of Strategy

Hans-Georg Rammensee Ph.D.

Co-Founder & Member of the Scientific Advisory Board

Harpreet Singh Ph.D.CEO

Chief Executive Officer, MD, Member of Management Board & Executive Director

Arnd Christ MBACFO

Chief Financial Officer

Management Team

Carsten Reinhardt M.D., Ph.D.

Chief Development Officer

Edward A. Sturchio

General Counsel & Secretary

Toni Weinschenk Ph.D.

Co-Founder & Chief Innovation Officer

Cedrik M. Britten M.D.

Chief Medical Officer

Jordan Silverstein

Head of Strategy

Hans-Georg Rammensee Ph.D.

Co-Founder & Member of the Scientific Advisory Board

Harpreet Singh Ph.D.CEO

Chief Executive Officer, MD, Member of Management Board & Executive Director

Arnd Christ MBACFO

Chief Financial Officer

Management

Carsten Reinhardt M.D., Ph.D.

Chief Development Officer

Edward A. Sturchio

General Counsel & Secretary

Toni Weinschenk Ph.D.

Co-Founder & Chief Innovation Officer

Cedrik M. Britten M.D.

Chief Medical Officer

Jordan Silverstein

Head of Strategy

Hans-Georg Rammensee Ph.D.

Co-Founder & Member of the Scientific Advisory Board

Harpreet Singh Ph.D.CEO

Chief Executive Officer, MD, Member of Management Board & Executive Director

Arnd Christ MBACFO

Chief Financial Officer

Total 8 executives

IMTX Frequently asked questions

What is Immatics N.V. (IMTX) Stock Price?

Current stock price of Immatics N.V. (IMTX) stock is $9.500. The stock price is +0.74% higher in the session. The intraday range can be seen from this page. Volume of Immatics N.V. (IMTX) stock is 736.11K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Immatics N.V. (IMTX) stock price going up or down today?

The stock price of Immatics N.V. (IMTX) can change with earnings, company news, and overall market sentiment. Immatics N.V. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Immatics N.V. stock expensive at its current price?

Whether Immatics N.V. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for IMTX on this page is -5.11. EPS on this page is -1.86. Compare those figures with peers and growth expectations before deciding if the current Immatics N.V. price is justified.

How has the stock price of Immatics N.V. (IMTX) performed historically?

Historical performance for Immatics N.V. (IMTX) is shown on the price chart on this page. Review multi-period moves alongside volume to see how IMTX reacted to past earnings and market events.

Should I buy Immatics N.V. (IMTX) stock, at this price?

Buying Immatics N.V. (IMTX) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.